Literature DB >> 48122

Second malignancies complicating Hodgkin's disease in remission.

G P Canellos, J C Arseneau, V T DeVita, J Whang-Peng, R E Johnson.   

Abstract

The incidence of second tumours occurring in the course of Hodgkin's disease has been investigated in a series of 452 patients treated with standard chemotherapy or radiotherapy, combination chemotherapy alone, intensive radiotherapy alone, or both intensive radiotherapy and combination chemotherapy administered in sequence. 16 tumours were noted. When analysed according to mode of treatment, 6 cases occurred in a group of 62 patients who received both modalities. When analysed for age, sex, and man-years of follow-up, this group appears to have 14-5 times the risk of developing a second tumour. However, that subgroup which had a complete remission after intensive radiotherapy followed by a relapse of disease, prior to receiving combination chemotherapy, had the highest risk with 18-5 times greater incidence of second tumour than expected. It is noteworthy that, of the 16 second tumours, 2 were acute myeloid leukaemia; in both cases a similar chromosomal abnormality (45 chromosomes, C-group deletion) was noted. The mechanism of oncogenesis may represent a combination of the immunosuppressive effects and cellular effects of those forms of treatment.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 48122     DOI: 10.1016/s0140-6736(75)92007-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  36 in total

Review 1.  MRI of radiation induced spinal cord glioma.

Authors:  C Bazan; P Z New; K S Kagan-Hallet
Journal:  Neuroradiology       Date:  1990       Impact factor: 2.804

2.  Radiation-induced spinal cord glioma subsequent to treatment of Hodgkin's disease: case report and review.

Authors:  Laurent Riffaud; Marc Bernard; Thierry Lesimple; Xavier Morandi
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

3.  The simultaneous presentation of Hodgkin's disease of myeloma.

Authors:  R M Ibbotson; P A Revell; E A Molland; M J Minton
Journal:  Postgrad Med J       Date:  1977-01       Impact factor: 2.401

4.  Immune function of successfully treated lymphoma patients.

Authors:  G W King; B Yanes; P E Hurtubise; S P Balcerzak; A F LoBuglio
Journal:  J Clin Invest       Date:  1976-06       Impact factor: 14.808

5.  Randomised trial of two-drug and four-drug maintenance chemotherapy in advanced or recurrent Hodgkin's disease. Medical Research Council's working party on lymphomas.

Authors:  P G Smith; N Wald
Journal:  Br Med J       Date:  1979-04-28

6.  Radiotherapy in the treatment of Hodgkin's disease.

Authors:  A R Timothy; S B Sutcliffe; A G Stansfeld; P F Wrigley; A E Jones
Journal:  Br Med J       Date:  1978-05-13

7.  Case report 409: Non-Hodgkin lymphoma (diffuse histiocytic or malignant lymphoma, diffuse, large cell B-cell immunophenotype).

Authors:  T S Samuels; B A Howard; J D Rubenstein; J Srigley
Journal:  Skeletal Radiol       Date:  1987       Impact factor: 2.199

Review 8.  Hodgkin's disease.

Authors:  T S Vats
Journal:  Indian J Pediatr       Date:  1987 Nov-Dec       Impact factor: 1.967

9.  Lung cancer following therapy for Hodgkin's disease.

Authors:  L Oliphant; R G McFadden
Journal:  Can Med Assoc J       Date:  1985-03-01       Impact factor: 8.262

10.  Lung carcinoma after radiotherapy and chemotherapy for Hodgkin's disease.

Authors:  R A Matthay; S K Zorn; M S Mitchell; R J Papac
Journal:  Thorax       Date:  1977-10       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.